Exacerbation of chronic active Epstein-Barr virus infection in a patient with rheumatoid arthritis receiving humanised anti-interleukin-6 receptor monoclonal antibody.
Ogawa
J
J
Harigai
M
M
Akashi
T
T
Nagasaka
K
K
Suzuki
F
F
Tominaga
S
S
Miyasaka
N
N
D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D002908:Chronic Disease; D020031:Epstein-Barr Virus Infections / Q000139:chemically induced*; D017809:Fatal Outcome; D005260:Female; D006801:Humans; D008875:Middle Aged; D009894:Opportunistic Infections / Q000139:chemically induced; D019947:Receptors, Interleukin-6 / Q000037:antagonists & inhibitors*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D019947:Receptors, Interleukin-6; C502936:tocilizumab